Vitamin D status of psychiatric inpatients in New Zealand's Waikato region.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968559 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-244X (Electronic) Linking ISSN: 1471244X NLM ISO Abbreviation: BMC Psychiatry Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Inpatients*; Mental Disorders/*complications ; Vitamin D/*blood ; Vitamin D Deficiency/*complications ; Vitamin D Deficiency/*diagnosis; Adolescent ; Adult ; Aged ; Ethnicity ; Female ; Humans ; Male ; Mental Disorders/blood ; Middle Aged ; New Zealand ; Vitamin D Deficiency/blood ; Vitamin D Deficiency/ethnology

Background: Vitamin D deficiency is widespread in New Zealand, confers multiple health risks, and may be particularly common among people with psychiatric illness. We studied vitamin D status in an unselected sample of adult psychiatric inpatients in Hamilton (latitude 37.5 S) during late winter.
Methods: We recruited 102 consenting subjects and measured 25-hydroxy vitamin D3 levels in venous blood using a competitive electrochemiluminescence immunoassay. In addition to descriptive statistics, we used one-sample t-tests to determine the extent to which ethnic and diagnostic subgroups fell below the vitamin D deficiency threshold of 50 nM.
Results: 75 subjects (74%) had vitamin D levels <50 nM and thus had at least mild deficiency, while 19 (19%) were severely deficient with levels <25 nM. Rates of deficiency were comparable for men and women; only the former showed a correlation of vitamin D levels with age (r = 0.45, p < 0.01). Maori participants constituted half the sample (n = 51) and were more likely to be deficient than their European counterparts (p = 0.04). Vitamin D also varied by diagnosis, with schizophrenia associated with markedly lower levels than mania and depression (p < 0.001).
Conclusions: Vitamin D deficiency is prevalent in the psychiatric inpatient setting in New Zealand and may be relevant to poor physical health outcomes, notably among Maori and those with schizophrenia. These findings support proposals to provide vitamin D supplementation, particularly during the winter months.

Schizophr Res. 2004 Apr 1;67(2-3):237-45. (PMID: 14984883)
N Z Med J. 2005 Nov 25;118(1226):U1752. (PMID: 16311610)
BMJ. 2010 Jan 11;340:b5664. (PMID: 20064851)
N Z Med J. 2007 Sep 21;120(1262):U2733. (PMID: 17891221)
J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):467-70. (PMID: 20214992)
Mayo Clin Proc. 2011 Jan;86(1):50-60. (PMID: 21193656)
N Engl J Med. 2007 Jul 19;357(3):266-81. (PMID: 17634462)
Am J Clin Nutr. 2011 Jul;94(1):225-33. (PMID: 21613551)
Med J Aust. 2001 Feb 5;174(3):150-1. (PMID: 11247622)
Mol Pharmacol. 2010 Sep;78(3):486-96. (PMID: 20558592)
Ann Intern Med. 2010 Mar 2;152(5):307-14. (PMID: 20194237)
J Neural Transm (Vienna). 2000;107(7):839-42. (PMID: 11005548)
Schizophr Bull. 2011 Mar;37(2):272-83. (PMID: 20974747)
Circulation. 2008 Jan 29;117(4):503-11. (PMID: 18180395)
J Intern Med. 2008 Dec;264(6):599-609. (PMID: 18793245)
Clin Chem. 2010 May;56(5):729-31. (PMID: 20348405)
Int Arch Med. 2010 Nov 11;3:29. (PMID: 21067618)
Mol Aspects Med. 2008 Dec;29(6):453-61. (PMID: 18786559)
J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):626-30. (PMID: 17218094)
J Nutr. 2005 Nov;135(11):2602-8. (PMID: 16251618)
Osteoporos Int. 2009 Aug;20(8):1407-15. (PMID: 19101755)
Osteoporos Int. 2005 Dec;16(12):1641-8. (PMID: 16027959)
Aust N Z J Psychiatry. 2008 Oct;42(10):874-8. (PMID: 18777231)
Osteoporos Int. 2006 Dec;17(12):1742-8. (PMID: 16932872)
Am J Clin Nutr. 2002 Apr;75(4):611-5. (PMID: 11916748)
Am J Clin Nutr. 2007 Mar;85(3):649-50. (PMID: 17344484)

1406-16-2 (Vitamin D)

Date Created: 20120628 Date Completed: 20130111 Latest Revision: 20220408

20231215

PMC3407027

10.1186/1471-244X-12-68

22734499